Aim: This study aims to investigate any modification of serological FSCN1 in prostate cancer patients compared with patients without neoplasia. Material & methods: Clinical data and blood specimens from patients with and without prostate cancer were obtained. A quantitative sandwich ELISA method was used to determine serological values of FSCN1. Results: Although serum values of FSCN1 were dissimilar in the two cohorts of patients (6.90 vs 7.33 ng/ml), the difference was not statistically significant (p = 0.20). Serum values of FSCN1 stratified for Gleason score groups were not significantly distinguishable (p = 0.65). A negative correlation (rho = -0.331; p = 0.009) was reported between FSCN1 and age. Conclusion: Further studies are required to evaluate a possible diagnostic role of FSCN1 in prostate cancer.
Fascin-1 and its role as a serological marker in prostate cancer: A prospective case-control study / Tataru, O. S.; Martha, O.; Crocetto, F.; Barone, B.; Voidazan, S.; Borda, A.; Sin, A.; Hutanu, A.; Loghin, A.; Sin, I.; Porav-Hodade, D.; Chibelean, C. B.; Vartolomei, L.; Lucarelli, G.; Ferro, M.; Osan, V. G.; Buonerba, C.; Vartolomei, M. D.. - In: FUTURE SCIENCE OA. - ISSN 2056-5623. - 7:9(2021), p. FSO745. [10.2144/fsoa-2021-0051]
Fascin-1 and its role as a serological marker in prostate cancer: A prospective case-control study
Crocetto F.;Barone B.;Buonerba C.;
2021
Abstract
Aim: This study aims to investigate any modification of serological FSCN1 in prostate cancer patients compared with patients without neoplasia. Material & methods: Clinical data and blood specimens from patients with and without prostate cancer were obtained. A quantitative sandwich ELISA method was used to determine serological values of FSCN1. Results: Although serum values of FSCN1 were dissimilar in the two cohorts of patients (6.90 vs 7.33 ng/ml), the difference was not statistically significant (p = 0.20). Serum values of FSCN1 stratified for Gleason score groups were not significantly distinguishable (p = 0.65). A negative correlation (rho = -0.331; p = 0.009) was reported between FSCN1 and age. Conclusion: Further studies are required to evaluate a possible diagnostic role of FSCN1 in prostate cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
